Short acting GLP-1 receptor agonist (injectable)
Lixisenatide 5 µg injection once daily
LIXI_SC_5UG_QD
Related
- All doses pooled: Lixisenatide injection
- Lixisenatide 20 ug subcutaneous once daily
- Lixisenatide 10 µg injection once daily
- Lixisenatide 30 µg injection once daily
- Lixisenatide 5 µg injection twice daily
- Lixisenatide 10 µg injection twice daily
- Lixisenatide 20 µg injection twice daily
- Lixisenatide 30 µg injection twice daily
- Lixisenatide 10 µg injection
- Lixisenatide 2.5 µg injection
- Lixisenatide 5 µg injection
- Lixisenatide 20 µg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.78 (0.01 to 58.74) | 0.41 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.29 (0.09 to 8.62) | 0.53 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.14 (0.00 to 1.78) | 0.85 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.09 (0.31 to 3.11) | 0.74 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 1.95 (0.29 to 8.75) | 0.58 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.60 (0.14 to 1.89) | 0.82 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.93 (0.05 to 15.26) | 0.45 |